EMA Authorised: Xbryk (denosumab) — Samsung Bioepis NL B.V.

View source ↗

Summary

The European Medicines Agency authorized Xbryk, a denosumab product from Samsung Bioepis NL B.V., for use in giant cell tumor of bone within the bone neoplasms …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Giant Cell Tumor of Bone

Drugs mentioned

• Xbryk (denosumab)

Snippet

Status: Authorised. Therapeutic area: Neoplasms, Bone Tissue;Giant Cell Tumor of Bone. MAH: Samsung Bioepis NL B.V.. Decision date: 10/07/2025